NCT07173751 2026-04-21
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
BioNTech SE
Phase 3 Recruiting
Clinical Trials
9 trialsNCT06382142 2026-04-20
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05570253 2026-04-17
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06343948 2026-04-17
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04345913 2026-04-13
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT07520760 2026-04-09
MBC-EA
Sun Yat-sen University
Phase 2 Recruiting
NCT05458674 2026-04-03
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Criterium, Inc.
Phase 2 Recruiting
NCT07494448 2026-03-27
JAZMINE
MedSIR
Phase 1/2 Not yet recruiting